N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo
about
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors.The endocannabinoid system as an emerging target of pharmacotherapyEndocannabinoids in the retina: from marijuana to neuroprotectionCharacterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assayThe involvement of TRPV1 in emesis and anti-emesisMarijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalizationN-Acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids - from fishy endocannabinoids to potential leadsThe CB2 receptor and its role as a regulator of inflammationConversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous systemThe endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cellsCharacterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA)N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptorsTRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the ratInternational Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertilityEndocannabinoid-mediated synaptic plasticity and addiction-related behaviorInhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.Cannabinoid 1 and transient receptor potential vanilloid 1 receptors discretely modulate evoked glutamate separately from spontaneous glutamate transmission.Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors.Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.Quantification of brain endocannabinoid levels: methods, interpretations and pitfallsModeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs.The role of endocannabinoids in pain modulation.Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays.Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake.Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels.Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor.N-octanoyl dopamine treatment of endothelial cells induces the unfolded protein response and results in hypometabolism and tolerance to hypothermia.Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.Characterization of the endocannabinoid system, CB(1) receptor signalling and desensitization in human myometrium.The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intakeThe endocannabinoid system: a general view and latest additionsCannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling.A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons.New insights on endocannabinoid transmission in psychomotor disorders.Evidence for bidirectional endocannabinoid transport across cell membranesThe therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.The endocannabinoid system: current pharmacological research and therapeutic possibilities.Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HTMetabolomic and Gene Expression Profiles Exhibit Modular Genetic and Dietary Structure Linking Metabolic Syndrome Phenotypes in Drosophila
P2860
Q24534526-BAEBF22C-2701-40E3-BDDB-6317CD6DB580Q24648473-21B88361-D266-4849-B333-4F4AF1B6640FQ24656049-0A3D05E5-3763-4A02-A112-6B2714343642Q24672180-B0C7C7C4-0643-4D85-B5B7-6377E4292DD0Q26745801-7EFB3F9B-C810-4F32-8608-A0E01D0A9BE7Q27009287-5A92475F-38F2-41E7-A3BB-3F555325CB58Q27011679-A8CC1E62-ACF5-4E00-904A-BF5022629E11Q28066700-E5210CF2-C6F5-444C-A62F-CA4F78A85923Q28182188-B59EA9E0-A6A2-484B-A8B3-42D1561AC35CQ28236199-DF6FECA6-DDAF-4030-9DB5-C3D446BD47F0Q28242911-27D49727-1BAB-4590-9958-B792CB10AD46Q28244889-EC30D43E-3B97-4D52-A192-35F643C3209FQ28271125-509E69F0-97B2-4DF1-ADBA-002931FA9910Q28298445-44CB92FA-D0B3-4244-8DD6-2F5975C7B7E7Q28303095-F90734CD-CFD3-4B57-8951-03D7C6441D9BQ29042501-C89F8761-152A-44A1-AEC3-13C06CE3FBF8Q33410345-2F11BE0A-8FDE-404B-BDFA-06419A596BCDQ33735535-023BC2C7-3762-4A26-BEB6-95EA7B205AA6Q33964434-7E05B30B-14D3-4005-8CB2-83B6FD5541B3Q33997873-C13875DE-310F-4361-A210-CB711660C620Q34098167-43C2F715-D757-4C35-9E06-916655C93179Q34222925-8A4DA34B-8116-4949-9650-F5F4378E8A50Q34320270-3EA90206-5799-4BDC-9DCE-11C61C9FDD55Q34442314-7790CB51-FF7A-49FE-872D-77C7086E57D4Q34557589-8C23EB51-B7D1-4778-AD9A-DFF910C42EF2Q35047663-A2444A03-3B11-4EA0-9BE3-90A7ED723154Q35100641-C9CF66BE-D2A6-41DC-91FF-DC0F88331D22Q35187579-896651D3-BA20-488C-A385-A3FEDEB2556FQ35532072-0517D313-4B46-478C-9BB7-B84ACA0E7A76Q35564284-4B7F8ECC-4CEC-4676-A2FB-98E1BF68AFEEQ35593066-EC314D44-9A4B-479E-99E1-88735D82D78DQ35639524-4CADC640-AD42-4001-9E56-B639FF5337E0Q35684044-9C5E1894-7D09-435D-A223-8E1CE29C5B6DQ35843085-57205587-382B-4EA5-92E3-2846D29ADEBBQ36074595-EFF8151A-A29F-4D9A-88E9-A0EE41F27B9CQ36298487-6806BB05-CE1D-4035-9ACD-C401D6E1CEBCQ36341688-59834DFE-1C86-44A6-BCC3-9DFF563523ABQ36381416-F59372F9-13A4-4FF9-AEAA-1B86C619D163Q36382959-435B5D0D-B61F-46FF-971F-F3DF5486FDEDQ36383185-8FE6E49A-816E-4B56-8FAC-ABA34895D4A4
P2860
N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@ast
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@en
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@en-gb
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@nl
type
label
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@ast
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@en
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@en-gb
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@nl
prefLabel
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@ast
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@en
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@en-gb
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@nl
P2093
P2860
P921
P3181
P1433
P1476
N-acyl-dopamines: novel synthe ...... activity in vitro and in vivo
@en
P2093
Bobrov MYu
L De Petrocellis
N M Gretskaya
V Di Marzo
V V Bezuglov
P2860
P304
P3181
P356
10.1042/0264-6021:3510817
10.1042/BJ3510817
P407
P478
P577
2000-11-01T00:00:00Z